ArcherDX, Inc. today announced that it has entered into a broad strategic collaboration with Genosity Inc., a biotechnology company that provides expertise, software and technical solutions to unlock the power of precision medicine by advancing genomics and facilitating collaborative research.
ArcherDX is pleased to announce the acquisition of Baby Genes, Inc, a privately held CLIA-certified, CAP-accredited laboratory focused on empowering individuals to take charge of their health through genetic insights.
ArcherDX announced that the U.S. Food and Drug Administration (FDA) granted a Breakthrough Device designation (formerly Expedited Access Pathway program) for ArcherDx’s companion diagnostic assay application.
Margaret Gulley, MD from the UNC School of Medicine describes her group’s method to quantify cancer mutations alongside tumor-related viral and bacterial pathogens in plasma and FFPE tissue using modified off-the-shelf Archer NGS reagents combined with Archer Analysis bioinformatics. She will discuss analytic and clinical interpretation criteria and the value of molecular barcodes and noise reduction algorithms in patient and control DNA.
In this webinar, Drs. Catherine Rehder and Sarah Rapisardo at Duke University describes their efforts to validate the Archer® VariantPlex® Myeloid assay. They also discuss their work to expand testing with a custom Archer FusionPlex® assay to detect known and novel fusions, with a focus on Ph-like ALL fusions.
ArcherDX and Merck KGaA, Darmstadt, Germany have entered into an agreement to develop and commercialize a next generation sequencing (NGS)-based companion diagnostic (CDx) assay.
Washington University in St. Louis and ArcherDX will partner on a study to characterize and assess minimum residual disease (MRD) across 870 pediatric patients with acute myeloid leukemia (AML) using next-generation sequencing (NGS).
Archer awards 5 recipients up to 96 free reactions (12 kits with 8 reactions each) of an Archer Assay in the fields of mutation tracking, liquid biopsy and immune repertoire.
ArcherDX and Ambry Genetics® announced today a partnership wherein Ambry will provide biopharma sequencing services employing ArcherDX’s next-generation sequencing (NGS) assays.
This year has proven to be exciting for ArcherDX, and we look forward to continuing this momentum into 2018. Some highlights include: ISO certification, CDx partnership with Celgene, new NGS-based myeloid assays, BCR sequencing assays, adoption of Reveal ctDNA kits, rapidly customizable panels, and software and analysis updates for an even greater level of variant calling confidence.
ArcherDX announces ISO 13485:2003 & EN ISO 13485:2012 certification indicating that the company’s quality management system maintains standards specific to medical devices, including in vitro diagnostic (IVD) assays
In this webinar we discuss how updates to the assay and software provide better coverage over challenging regions and enable lower limits of detection, high-resolution CNV detection and lightning-fast analysis that leverage and maximize the unique power of the patented Anchored Multiplex PCR (AMP™) target enrichment chemistry used in Archer NGS assays.
ArcherDX launches two new NGS-based NGS-based variant-detection assays, the 37-gene VariantPlex Core Myeloid and 72-gene VariantPlex Myeloid panel with unprecedented levels of confident mutation detection.
ArcherDX is partnering with Susan G. Komen Colorado and the University of Colorado Cancer Center to create a local event to connect community physicians, patients, and advocates with academic researchers and industry leaders. Our vision is to provide an educational forum to raise awareness about advances in breast cancer research, treatment, and testing.
Archer exhibits at the American Association of Immunologists Annual Meeting–Immunology 2017 in Washington, DC. At the largest annual gathering of immunologists worldwide, scientists discuss breakthroughs across the full spectrum of topics in the Immunology.
ArcherDX, Inc. today announced that it has entered into a broad strategic collaboration with Genosity Inc., a biotechnology company that provides expertise, software and technical solutions to unlock the power of precision medicine by advancing genomics and facilitating collaborative research.
For Research Use Only. Not for use in diagnostic procedures.
Having trouble getting the documents using Chrome Browser? Make sure you're using the default zoom factor by pressing Control + 0 on a PC or Command + 0 on a Mac. Hover over the PDF in this window and the download button should appear in a black bar at the top.